Market Intelligence, Clinical Progress, and High-Purity Reagents for Vascular Leakage and Angiogenesis Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ROBO4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ROBO4 ECD-Fc Protein High purity (>95%), Endotoxin Controlled (<1 EU/µg). Sequence Verified. HEK293 Expressed for native glycosylation. |
View ROBO4 Products |
| Gene Delivery | ROBO4 Lentivirus Premade Particles Full-length ORF for stable cell line construction and functional endothelial barrier assays. |
View ROBO4 Products |
| Benchmark Ab | Anti-ROBO4 Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View ROBO4 Products |
| Validator | ROBO4 siRNA Set Target-specific knockdown pool for specificity and target validation. |
View ROBO4 Products |
| Related Target A | SLIT2 Primary ligand for ROBO receptors; critical for evaluating ROBO4-mediated vascular stabilization. |
View SLIT2 Products |
| Related Target B | UNC5B Co-receptor interacting with ROBO4 to maintain vascular endothelial barrier integrity. |
View UNC5B Products |
| Related Target C | VEGFR2 Key driver of vascular permeability; targeted synergistically alongside ROBO4 in ocular diseases. |
View VEGFR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation (Cyno/Mouse) | Human, Cynomolgus, and Mouse ROBO4 recombinant proteins available with >95% purity verified by SDS-PAGE. |
| Subfamily off-target screening (ROBO1/2/3) | Homolog panel proteins strictly verified by mass spectrometry to ensure sequence identity and minimize cross-reactivity. |
| Lack of functional validation controls | Sequence-verified clinical benchmark antibodies available as positive controls for binding and functional assays. |
| False positives in phenotypic screens | Validated siRNA sets included to confirm target-specific phenotypic outcomes in endothelial cell assays. |
Live ROBO4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ROBO4 therapeutics is intensifying, with major players shifting focus from traditional oncology-focused anti-angiogenesis to vascular stabilization in ocular and systemic inflammatory diseases. As first-generation therapies targeting vascular endothelial growth factors (VEGF) face resistance or sub-optimal responses in diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), the next wave of R&D is targeting ROBO4 to preserve endothelial barrier function and prevent pathological vascular leak.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Agonistic) | Roche, Academic Spin-offs | Diabetic Macular Edema (DME), Wet AMD, Sepsis | Endothelial Barrier Assays (Requires Lentivirus for stable ROBO4-expressing cell lines) |
| Bispecific Antibody (ROBO4 x VEGF) | Biotech Integrators | Neovascular Eye Diseases, Solid Tumors | Dual-binding Affinity Verification (Requires high-purity ROBO4 and VEGFR2 ECD proteins) |
| Soluble Receptor (Decoy Fc) | Oncology Biotechs | Tumor Angiogenesis, Metastasis | Ligand Competition Assays (Requires high-purity SLIT2 and UNC5B proteins) |